Jun Gong, Fellow, City of Hope presents Latency of potential treatment-related adverse events among patients treated with TKI/VEGF-directed therapy for metastatic renal cell carcinoma (mRCC) at the 2016 annual International Kidney Cancer Symposium.
Latency of potential treatment-related adverse events among patients treated with TKI/VEGF-directed therapy for metastatic renal cell carcinoma (mRCC)
